Navigation Links
AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
Date:1/13/2010

WILMINGTON, Del., Jan. 13 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that enrollment and re-enrollment for two of its prescription savings programs is available online for the first time at www.azandme.com.

In addition, online self-service options are available for both programs, which enable health care providers, advocates and patients to order and monitor the shipping of refills and check the status of their enrollment online at www.azandme.com. AstraZeneca is the first pharmaceutical company to provide these self-service options directly to patients.

"We are using more tools to help patients get the medicines and information they need in an efficient and timely way," said Jennifer McGovern, AstraZeneca Director of Patient Assistance Programs. "We hope to be able to better serve patients and the people who support them by continually making program enhancements."

For over 30 years, AstraZeneca has offered patient assistance, because the company knows that medicines can only make a difference if patients can access them. Web-based improvements are another way that AstraZeneca is strengthening its commitment to patient health.

Program Details

To learn more about the program, get a list of available medicines, or to see if you qualify for an AZ&Me™ Prescription Savings program, please call  1-800-AZandMe (292-6363) or visit www.azandme.com. Assistance specialists are available Monday through Friday between 8 AM and 6 PM EST.

For those who prefer completing a hard-copy application, the AZ&Me™ Prescription Savings program for people without insurance and for people with Medicare Part D now also offers one streamlined application for both programs.  The application is available in English and Spanish at www.azandme.com or by calling 1-800-AZandMe (292-6363).

Prescription savings programs are available regardless of which medications doctors prescribe. To find out more about the more than 475 savings programs covering 2,500 medications, please visit www.pparx.org or call 1-888-4PPA-NOW (1-888-477-2669).

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com.

SOURCE AstraZeneca

RELATED LINKS
http://www.astrazeneca-us.com

'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novexel to be Acquired by AstraZeneca
2. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
3. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
4. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
5. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
6. Jubilant Enters Research Collaboration With AstraZeneca
7. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
8. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
9. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
10. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
11. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Australia Ophthalmic Lasers Market Outlook to ... Lasers Market Outlook to 2022", provides key market data ... value, in millions of US dollars, volume (in units) ... Lasers, Femtosecond Lasers and YAG Lasers. The report ... each of these market segements, and global corporate-level profiles ...
(Date:12/8/2016)... Global Interventional Radiology Market: Scope and ... radiology market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/8/2016)... -- Allergy Diagnostics Market: Scope and Methodology ... used to determine the presence of allergens such ... in the samples by determining the presence of ... on global allergy diagnostics market, analyzes the current ... consists of an executive summary that provides information ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... 10th anniversary with the grand opening of the Sober College Robert Pfeifer Memorial ... two days, December 2-3, and was attended by an overwhelming amount of alumni, ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... , ... With the increasing demand for dental implants, the National Association of ... inform dentists and patients about the safety issues related to dental restorations. According to ... U.S. is projected to reach $6.4 billion in 2018 with more than 30 million ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):